Aldehyde Salt Dry Form for Valsartan Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current industrial-scale manufacturing processes for blood pressure lowering agents like valsartan face challenges due to the use of aldehydes in a 'wet' form, leading to inefficiencies and increased impurities, which complicates handling and results in lower yields and higher waste production.
Innovation Solution
The use of stable salts of the aldehyde in dry form, allowing for improved handling, storage, and reaction conditions, which facilitates a more defined and efficient synthesis process with reduced impurities and byproducts, enabling better economic and ecological outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If aldehyde is used in wet form for industrial-scale manufacturing, then handling is simpler, but impurity levels increase and yield decreases
Solution Approach 1:
The patent converts the aldehyde from wet form to dry salt form, changing the physical state and water content parameters. This transformation allows the substance to be handled as a stable solid while eliminating water-related impurity issues, thus resolving the contradiction between ease of handling and manufacturing precision
Solution Approach 2:
The patent creates a composite salt structure by combining the aldehyde with metal cations (such as sodium, potassium, or ammonium). This composite form provides both the chemical reactivity needed for the reaction and the physical stability required for dry handling, eliminating the need for aqueous solutions while maintaining operational convenience
2Device complexity
If aldehyde is used in wet form, then process simplicity is maintained, but waste production increases
Solution Approach 1:
By changing the form from wet aldehyde to dry salt, the patent eliminates water as a solvent and waste stream. The process becomes simpler in terms of waste treatment while reducing overall waste volume, as the salt form requires no aqueous workup or drying steps
Solution Approach 2:
The patent eliminates the need to discard large volumes of aqueous waste by using dry salt form. The process design recovers materials more efficiently by avoiding water-based reactions, thus reducing substance loss and waste generation without complicating the overall process
3Use of energy by moving object
If aldehyde is used in wet form, then energy consumption is higher, but reaction definition decreases
Solution Approach 1:
The patent changes the physical state from aqueous solution to dry solid, eliminating the energy required for heating, stirring, and drying large volumes of water. The dry salt form allows for more defined reaction conditions with better control over stoichiometry and reaction progress, improving process definition while reducing energy consumption
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of aldehyde salts in dry form enhances the manufacturing process by reducing impurities, improving yield, and minimizing waste and energy consumption, resulting in a safer and more efficient production method for valsartan and other angiotensin receptor blockers.
Implementation Method 1
the manufacture of an intermediate of the formula I as anion with a cation and thus in the form of a salt
Data Source
AI summary
The invention relates to a method or process for the manufacture of blood pressure lowering agents, such as valsartan, novel intermediates as well as process steps in said synthesis. The method or process leads via the novel intermediate salts of the formula (IA), or a tautomer thereof, wherein [Kat]n+ is a cation and n is 1, 2, 3, 4, 5 or 6.